Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has clinical programs underway for such areas of major unmet medical need as irritable bowel syndrome and cognitive disorders. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Company, Genentech, Inc. and N.V. Organon. For additional information about Lexicon and its programs, please visit http://www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements," including
statements relating to Lexicon's growth and future operating results,
discovery and development of products, strategic alliances and intellectual
property, as well as other matters that are not historical facts or
information. All forward-looking statements are based on management's
current assumptions and expectations and involve risks, uncertainties and
other important factors that may cause Lexicon's actual results to be
materially different from any future results expressed or implied by such
forward-looking statements. Information identifying such important factors
is contained under "Factors Affecting Forward-Looking Statements" and "Risk
Factors" in Lexicon's annual report on Form 10-K for the year ended
December 31, 2006, as filed with the Securities and Exchange Commission.
Lexicon undertakes no obligation to update or revise
|SOURCE Lexicon Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved